Literature DB >> 16618742

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

Marie Wislez1, Nobukazu Fujimoto, Julie G Izzo, Amy E Hanna, Dianna D Cody, Robert R Langley, Hongli Tang, Marie D Burdick, Mitsuo Sato, John D Minna, Li Mao, Ignacio Wistuba, Robert M Strieter, Jonathan M Kurie.   

Abstract

CXCL8, a ligand for the chemokine receptor CXCR2, was recently reported to be a transcriptional target of Ras signaling, but its role in Ras-induced tumorigenesis has not been fully defined. Here, we investigated the role of KC and MIP-2, the murine homologues of CXCL8, in Kras(LA1) mice, which develop lung adenocarcinoma owing to somatic activation of the KRAS oncogene. We first investigated biological evidence of CXCR2 ligands in Kras(LA1) mice. Malignant progression of normal alveolar epithelial cells to adenocarcinoma in Kras(LA1) mice was associated with enhanced intralesional vascularity and neutrophilic inflammation, which are hallmarks of chemoattraction by CXCR2 ligands. In in vitro migration assays, supernatants of bronchoalveolar lavage samples from Kras(LA1) mice chemoattracted murine endothelial cells, alveolar inflammatory cells, and the LKR-13 lung adenocarcinoma cell line derived from Kras(LA1) mice, an effect that was abrogated by pretreatment of the cells with a CXCR2-neutralizing antibody. CXCR2 and its ligands were highly expressed in LKR-13 cells and premalignant alveolar lesions in Kras(LA1) mice. Treatment of Kras(LA1) mice with a CXCR2-neutralizing antibody inhibited the progression of premalignant alveolar lesions and induced apoptosis of vascular endothelial cells within alveolar lesions. Whereas the proliferation of LKR-13 cells in vitro was resistant to treatment with the antibody, LKR-13 cells established as syngeneic tumors were sensitive, supporting a role for the tumor microenvironment in the activity of CXCR2. Thus, high expression of CXCR2 ligands may contribute to the expansion of early alveolar neoplastic lesions induced by oncogenic KRAS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618742     DOI: 10.1158/0008-5472.CAN-05-3842

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  85 in total

1.  Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis.

Authors:  Haris G Vikis; Andrew E Gelman; Andrew Franklin; Lauren Stein; Amy Rymaszewski; Jihong Zhu; Pengyuan Liu; Jay W Tichelaar; Alexander S Krupnick; Ming You
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

Review 2.  The role of CXC chemokines in pulmonary fibrosis.

Authors:  Robert M Strieter; Brigitte N Gomperts; Michael P Keane
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice.

Authors:  Elizabeth F Redente; David J Orlicky; Ronald J Bouchard; Alvin M Malkinson
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 4.  Update in lung cancer 2006.

Authors:  Sarita Dubey; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2007-05-01       Impact factor: 21.405

Review 5.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 6.  Chemokines as mediators of tumor angiogenesis and neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Exp Cell Res       Date:  2010-10-30       Impact factor: 3.905

7.  VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.

Authors:  Virginie Hervé; Nathalie Rabbe; Laurent Guilleminault; Flora Paul; Laurène Schlick; Nicolas Azzopardi; Michael Duruisseaux; Delphine Fouquenet; Jérôme Montharu; Françoise Redini; Gilles Paintaud; Etienne Lemarié; Jacques Cadranel; Marie Wislez; Nathalie Heuzé-Vourc'h
Journal:  MAbs       Date:  2014       Impact factor: 5.857

8.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

9.  G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis.

Authors:  Sandeep K Raghuwanshi; Nikia Smith; Elizabeth J Rivers; Ariel J Thomas; Natalie Sutton; Yuhui Hu; Somnath Mukhopadhyay; Xiaoxin L Chen; TinChung Leung; Ricardo M Richardson
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 10.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.